Clinical significance and comparison of flotillin 1 expression in left and right colon cancer

Baig,Nadia; Li,Zequn; Lu,Jing; Chen,Haibin; Yu,Songyang; Li,Tianen; Niu,Zhaojian; Niu,Jun

doi:10.3892/ol.2019.10401

Clinical significance and comparison of flotillin 1 expression in left and right colon cancer

Authors:
- Nadia Baig
- Zequn Li
- Jing Lu
- Haibin Chen
- Songyang Yu
- Tianen Li
- Zhaojian Niu
- Jun Niu
View Affiliations

Affiliations: Department of General Surgery, Qilu Hospital of Shandong University, Jinan, Shandong 250012, P.R. China, Department of Gastrointestinal Surgery, Affiliated Hospital of Qingdao University, Qingdao, Shandong 266000, P.R. China, Department of Chemotherapy, Qilu Hospital of Shandong University, Jinan, Shandong 250012, P.R. China
Published online on: May 27, 2019 https://doi.org/10.3892/ol.2019.10401
Pages: 997-1004
Copyright: © Baig et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Flotillin 1 (FLOT1) is increasingly implicated in various types of cancer, and has been reported to influence tumorigenesis and cancer progression, leading to poor prognosis for survival time; however, its expression in colorectal cancer (CRC) and its influence on various clinicopathological parameters of this disease remain unknown. In the present study, FLOT1 expression and its effect on different clinicopathological parameters were assessed immunohistochemically and histologically in 81 CRC and 81 non‑tumorous colon tissue samples. The immunohistochemical staining was scored semi‑quantitatively. The association of FLOT1 expression with various parameters and its effect on overall survival time was also assessed. FLOT1 was upregulated in the CRC tissue, with increased expression in the right colon tissue samples compared with those of left colon. Increased FLOT1 expression in CRC tissue samples was associated with tumor volume, differentiation, tumor grade and poor overall survival time. In the right colon tissue samples in particular, there was a notable association with tumor volume and grade, indicating its effect on proliferation and tumor stage at this site. A multivariate Cox regression hazard analysis revealed that only tumor grade and differentiation were the independent predictors of overall survival time in patients with CRC. Together, the results of the present study suggest that FLOT1 serves important functions in the proliferation and progression of CRC, contributes to decreased survival time, and may serve as a novel therapeutic target for the treatment of CRC.

View Figures

View References

1	Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
2	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2018. CA Cancer J Clini. 68:7–30. 2018. View Article : Google Scholar
3	Tuan J and Chen YX: Dietary and lifestyle factors associated with colorectal cancer risk and interactions with microbiota: Fiber, red or processed meat and alcoholic drinks. Gastrointest Tumors. 3:17–24. 2016. View Article : Google Scholar : PubMed/NCBI
4	Laohavinij S, Maneechavakajorn J and Techatanol P: Prognostic factors for survival in colorectal cancer patients. J Med Assoc Thai. 93:1156–1166. 2010.PubMed/NCBI
5	Hansen IO and Jess P: Possible better long-term survival in left versus right-sided colon cancer - A systematic review. Dan Med J. 59:A44442012.PubMed/NCBI
6	Wray CM, Ziogas A, Hinojosa MW, Le H, Stamos MJ and Zell JA: Tumor subsite location within the colon is prognostic for survival after colon cancer diagnosis. Dis Colon Rectum. 52:1359–1366. 2009. View Article : Google Scholar : PubMed/NCBI
7	Benedix F, Kube R, Meyer F, Schmid U, Gastinger I and Lippert H; Colon/Rectum Carcinomas and (Primary Tumor) Study Group, : Comparison of 17,641 patients with right- and left-sided colon cancer: Differences in epidemiology, perioperative course, histology, and survival. Dis Colon Rectum. 53:57–64. 2010. View Article : Google Scholar : PubMed/NCBI
8	Hutchins G, Southward K, Handley K, Magill L, Beaumont C, Stahlschmidt J, Richman S, Chambers P, Seymour M, Kerr D, et al: Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer. J Clini Oncol. 29:1261–1270. 2011. View Article : Google Scholar
9	Elnatan J, Goh HS and Smith DR: C-KI-RAS activation and the biological behaviour of proximal and distal colonic adenocarcinomas. Eur J Cancer 32A. 491–497. 1996. View Article : Google Scholar
10	Babuke T and Tikkanen R: Dissecting the molecular function of reggie/flotillin proteins. Eur J Cell Biol. 86:525–532. 2007. View Article : Google Scholar : PubMed/NCBI
11	Langhorst MF, Reuter A and Stuermer CA: Scaffolding microdomains and beyond: The function of reggie/flotillin proteins. Cell Mol Life Sci. 62:2228–2240. 2005. View Article : Google Scholar : PubMed/NCBI
12	Winship AL, Rainczuk K and Dimitriadis E: Flotillin-1 protein is upregulated in human endometrial cancer and localization shifts from epithelial to stromal with increasing tumor grade. Cancer Investigat. 34:26–31. 2016. View Article : Google Scholar
13	Yang FQ, Zhang HM, Chen SJ, Yan Y and Zheng JH: MiR-506 is down-regulated in clear cell renal cell carcinoma and inhibits cell growth and metastasis via targeting FLOT1. PLoS One. 10:e01202582015. View Article : Google Scholar : PubMed/NCBI
14	Guan Y, Song H, Zhang G and Ai X: Overexpression of flotillin-1 is involved in proliferation and recurrence of bladder transitional cell carcinoma. Oncol Rep. 32:748–754. 2014. View Article : Google Scholar : PubMed/NCBI
15	Li H, Zhang Y, Chen SW, Li FJ, Zhuang SM, Wang LP, Zhang J and Song M: Prognostic significance of Flotillin1 expression in clinically N0 tongue squamous cell cancer. Int J Clini Exp Pathol. 7:996–1003. 2014.
16	Gao W, Xu J, Wang F, Zhang L, Peng R, Shu Y, Wu J, Tang Q and Zhu Y: Plasma membrane proteomic analysis of human gastric cancer tissues: Revealing flotillin 1 as a marker for gastric cancer. BMC Cancer. 15:3672015. View Article : Google Scholar : PubMed/NCBI
17	Li L, Luo J, Wang B, Wang D, Xie X, Yuan L, Guo J, Xi S, Gao J, Lin X, et al: Microrna-124 targets flotillin-1 to regulate proliferation and migration in breast cancer. Mol Cancer. 12:1632013. View Article : Google Scholar : PubMed/NCBI
18	Arkhipova KA, Sheyderman AN, Laktionov KK, Mochalnikova VV and Zborovskaya IB: Simultaneous expression of flotillin-1, flotillin-2, stomatin and caveolin-1 in non-small cell lung cancer and soft tissue sarcomas. BMC Cancer. 14:1002014. View Article : Google Scholar : PubMed/NCBI
19	Li Z, Yang Y, Gao Y, Wu X, Yang X, Zhu Y, Yang H, Wu L, Yang C and Song L: Elevated expression of flotillin-1 is associated with lymph node metastasis and poor prognosis in early-stage cervical cancer. Ameri J Cancer Res. 6:38–50. 2015.
20	Zhang SH, Wang CJ, Shi L, Li XH, Zhou J, Song LB and Liao WT: High expression of FLOT1 is associated with progression and poor prognosis in hepatocellular carcinoma. PLoS One. 8:e647092013. View Article : Google Scholar : PubMed/NCBI
21	Gomez V, Sese M, Santamaria A, Martínez JD, Castellanos E, Soler M, Thomson TM and Paciucci R: Regulation of aurora B kinase by the lipid raft protein flotillin-1. J Biological Chem. 285:20683–20690. 2010. View Article : Google Scholar
22	Ou YX, Liu FT, Chen FY and Zhu ZM: Prognostic value of Flotillin-1 expression in patients with solid tumors. Oncotarget. 8:52665–52677. 2017. View Article : Google Scholar : PubMed/NCBI
23	Kim SH, Ha TK and Kwon SJ: Evaluation of the 7th AJCC TNM staging system in point of lymph node classification. J Gastric Cancer. 11:94–100. 2011. View Article : Google Scholar : PubMed/NCBI
24	Thorn CC, Freeman TC, Scott N, Guillou PJ and Jayne DG: Laser microdissection expression profiling of marginal edges of colorectal tumours reveals evidence of increased lactate metabolism in the aggressive phenotype. Gut. 58:404–412. 2009. View Article : Google Scholar : PubMed/NCBI
25	Niu Y, Shao Z, Wang H, Yang J, Zhang F, Luo Y, Xu L, Ding Y and Zhao L: LASP1-S100A11 axis promotes colorectal cancer aggressiveness by modulating TGFβ/Smad signaling. Sci Rep. 6:261122016. View Article : Google Scholar : PubMed/NCBI
26	Pust S, Klokk TI, Musa N, Jenstad M, Risberg B, Erikstein B, Tcatchoff L, Liestøl K, Danielsen HE, van Deurs B, et al: Flotillins as regulators of ErbB2 levels in breast cancer. Oncogene. 32:3443–3451. 2013. View Article : Google Scholar : PubMed/NCBI
27	Nawa T, Kato J, Kawamoto H, Okada H, Yamamoto H, Kohno H, Endo H and Shiratori Y: Differences between right- and left-sided colon cancer in patient characteristics, cancer morphology and histology. J Gastroenterol Hepatol. 23:418–423. 2008. View Article : Google Scholar : PubMed/NCBI
28	Rothberg PG, Spandorfer JM, Erisman MD, Staroscik RN, Sears HF, Petersen RO and Astrin SM: Evidence that c-myc expression defines two genetically distinct forms of colorectal adenocarcinoma. Br J Cancer. 52:629–632. 1985. View Article : Google Scholar : PubMed/NCBI
29	Gervaz P, Bouzourene H, Cerottini JP, Chaubert P, Benhattar J, Secic M, Wexner S, Givel JC and Belin B: Dukes B colorectal cancer: Distinct genetic categories and clinical outcome based on proximal or distal tumor location. Dis Colon Rectum. 44:364–372. 2001. View Article : Google Scholar : PubMed/NCBI